Cloning, expression, purification and functional characterization of the oligomerization domain of Bcr-Abl oncoprotein fused to the cytoplasmic transduction peptide

Protein Expression and Purification

Volumn 64, Issue 2, 2009, Pages 167-178

  Huang, Shi feng ^a   Liu, Ding bin ^a   Zeng, Jian ming ^a   Xiao, Qing ^b   Luo, Miao ^a   Zhang, Wen ping ^a   Tao, Kun ^a   Wen, Jian ping ^c   Huang, Zong gan ^b   Feng, Wen li ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c CANADIAN BLOOD SERVICES   (Canada)

Author keywords

Bcr Abl; Cytoplasmic transduction peptide; Oligomerization domain; Protein expression; Protein purification; Protein transduction

Indexed keywords

BCR ABL PROTEIN; PEPTIDE; RECOMBINANT PROTEIN;

ARTICLE; CELL CULTURE; CELL STRAIN K 562; CHEMISTRY; CONFOCAL MICROSCOPY; CYTOPLASM; GENE EXPRESSION; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR CLONING; PROTEIN TERTIARY STRUCTURE;

CELLS, CULTURED; CLONING, MOLECULAR; CYTOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; HUMANS; K562 CELLS; MICROSCOPY, CONFOCAL; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS;

ESCHERICHIA COLI;

EID: 58749104517     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2008.10.023     Document Type: Article

References (27)

1. Zhao X., Ghaffari S., Lodish H., Malashkevich V.N., and Kim P.S. Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat. Struct. Mol. Biol. 9 (2002) 117-120
2. Smith K.M., Yacobi R., and Van Etten R.A. Autoinhibition of Bcr-Abl through Its SH3 domain. Mol. Cell 12 (2003) 27-37
3. Mauro M.J., and Druker B.J. STI571: a gene product-targeted therapy for leukemia. Curr. Oncol. Rep. 3 (2001) 223-227
4. Hochhaus A., Kreil S., Corbin A., La Rosée P., Lahaye T., Berger U., Cross N.C., Linkesch W., Druker B.J., Hehlmann R., Gambacorti-Passerini C., Corneo G., and D'Incalci M. Roots of clinical resistance to STI-571 cancer therapy. Science 293 (2001) 2163
5. Guo X.Y., Cuillerot J.M., Wang T., Wu Y., Arlinghaus R., Claxton D., Bachier C., Greenberger J., Colombowala I., and Deisseroth A.B. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells. Oncogene 17 (1998) 825-833
6. Check E. Gene therapy: shining hopes dented-but not dashed. Nature 420 (2002) 735
7. Connolly J.B. Lentiviruses in gene therapy clinical research. Gene Ther. 9 (2002) 1730-1734
8. Cornetta K., Morgan R.A., and Anderson W.F. Safety issues related to retroviral-mediated gene transfer in humans. Hum. Gene Ther. 2 (1991) 5-14
9. Marshall E. Viral threat to newborns under radar. Science 295 (2002) 1631
10. Chauhan A., Tikoo A., Kapur A.K., and Singh M. The taming of the cell penetrating domain of the HIV Tat: Myths and realities. J. Control. Release 117 (2007) 148-162
11. Kim D., Jeon C., Kim J.H., Kim M.S., Yoon C.H., Choi I.S., Kim S.H., and Bae Y.S. Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo. Exp. Cell Res. 312 (2006) 1277-1288
12. Vives E., Brodin P., and Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272 (1997) 16010-16017
13. Sandgren S., Cheng F., and Belting M. Nuclear targeting of macromolecular polyanions by an HIV-Tat derived peptide. Role for cell-surface proteoglycans. J. Biol. Chem. 277 (2002) 38877-38883
14. Ferrari A., Pellegrini V., Arcangeli C., Fittipaldi A., Giacca M., and Beltram F. Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. Mol. Ther. 8 (2003) 284-294
15. Wadia J.S., Stan R.V., and Dowdy S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10 (2004) 310-315
16. Lundberg M., and Johansson M. Is VP22 nuclear homing an artifact?. Nat. Biotechnol. 19 (2001) 713-714
17. Leifert J.A., Harkins S., and Whitton J.L. Full-length proteins attached to the HIV tat protein transduction domain are neither transduced between cells, nor exhibit enhanced immunogenicity. Gene Ther. 9 (2002) 1422-1428
18. Richard J.P., Melikov K., Vives E., Ramos C., Verbeure B., Gait M.J., Chernomordik L.V., and Lebleu B. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278 (2003) 585-590
19. Lundberg M., Wikstrom S., and Johansson M. Cell surface adherence and endocytosis of protein transduction domains. Mol. Ther. 8 (2003) 143-150
20. Chauhan A., Turchan J., Pocernich C., Bruce-Keller A., Roth S., Butterfield D.A., Major E.O., and Nath A. Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J. Biol. Chem. 278 (2003) 13512-13519
21. Siomi H., Shida H., Maki M., and Hatanaka M. Effects of a highly basic region of human immunodeficiency virus Tat protein on nucleolar localization. J. Virol. 64 (1990) 1803-1807
22. Brask J., Chauhan A., Hill R.H., Ljunggren H.G., and Kristensson K. Effects on synaptic activity in cultured hippocampal neurons by influenza A viral proteins. J. Neurovirology 11 (2005) 395-402
23. Hu M., Chen P., Wang J., Scollard D.A., Vallis K.A., and Reilly R.M. (123)I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21 (WAF-1/Cip-1). Eur. J. Nucl. Med. Mol. Imaging 34 (2007) 368-377
24. Cashman S.M., Morris D.J., and Kumar-Singh R. Evidence of protein transduction but not intercellular transport by proteins fused to HIV tat in retinal cell culture and in vivo. Mol. Ther. 8 (2003) 130-142
25. Weinberger L.S., Burnett J.C., Toettcher J.E., Arkin A.P., and Schaffer D.V. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell 122 (2005) 169-182
26. Michienzi A., Li S., Zaia J.A., and Rossi J.J. A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc. Natl. Acad. Sci. USA 99 (2002) 14047-14052
27. Lindsay M.A. Peptide-mediated cell delivery: application in protein target validation. Curr. Opin. Pharmacol. 2 (2002) 587-594